Trial Profile
VP-VLY-686-3301: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study To Assess The Efficacy Of Tradipitant In Relieving Symptoms Of Gastroparesis
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Tradipitant (Primary)
- Indications Diabetic gastroparesis; Gastroparesis
- Focus Registrational; Therapeutic Use
- Sponsors Vanda Pharmaceuticals
- 06 Mar 2024 Planned number of patients changed from 450 to 900.
- 06 Mar 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 06 Mar 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.